Fortress Biotech, Inc. (FBIO)
2.68
-0.06
(-2.01%)
USD |
NASDAQ |
Sep 01, 16:00
2.68
0.00 (0.00%)
Pre-Market: 08:09
Fortress Biotech Research and Development Expense (Annual) : 11.90M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 11.90M |
| December 31, 2024 | 56.88M |
| December 31, 2023 | 106.07M |
| December 31, 2022 | 134.88M |
| December 31, 2021 | 128.86M |
| December 31, 2020 | 64.11M |
| December 31, 2019 | 81.33M |
| December 31, 2018 | 87.38M |
| December 31, 2017 | 52.49M |
| Date | Value |
|---|---|
| December 31, 2016 | 35.13M |
| December 31, 2015 | 29.81M |
| December 31, 2014 | 9.372M |
| December 31, 2013 | 25.68M |
| December 31, 2012 | 17.47M |
| December 31, 2011 | 8.583M |
| December 31, 2010 | 8.341M |
| December 31, 2009 | 2.27M |
| December 31, 2008 | 2.895M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Inovio Pharmaceuticals, Inc. | 52.79M |
| Ironwood Pharmaceuticals, Inc. | 93.26M |
| Kura Oncology, Inc. | 251.07M |
| Spero Therapeutics, Inc. | 38.47M |
| Cue Biopharma, Inc. | 37.43M |